Sequence Bio is a local biotech company leading the NL Genome Project to research the one-of-a-kind genetic makeup of our province and improve how we treat and prevent diseases that impact us most.
The NL Genome Project launched in June, 2019, and aims to gain a deeper understanding of Newfoundland and Labrador’s unique population by studying volunteering, consenting participants’ DNA (through a saliva sample) in combination with their medical records. By combining this information with advanced statistical and computational analysis, we hope to find genetic changes that could help explain the link between genetics, health, and disease and lead to the discovery of better, safer medicines.
Sequence Bio is committed to benefiting individuals, families and communities in Newfoundland and Labrador for generations to come, and spent 5 years building the right ethical and legislative framework to run this project. Participants can choose whether they want to receive research-grade findings about their genetic makeup that may help guide treatment options and outcomes, and Sequence Bio is also working to share future potential discoveries with local researchers, policy makers, and doctors to help integrate precision medicine into the care we receive at home.
For more information, visit:
Sequence Bio: www.sequencebio.com
NL Genome Project: www.nlgenomeproject.ca
Sequence Bio is a Newfoundland and Labrador biotechnology company striving to improve how we treat diseases and develop medicines.